Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.31 EUR
Change Today +0.009 / 0.39%
Volume 0.0
FFEA On Other Exchanges
Symbol
Exchange
Continuous
OTC US
Berlin
Continuous
As of 10:03 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

faes farma sa (FFEA) Snapshot

Open
€2.38
Previous Close
€2.30
Day High
€2.38
Day Low
€2.29
52 Week High
05/20/15 - €2.44
52 Week Low
01/5/15 - €1.54
Market Cap
572.7M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
247.9M
EX-Date
12/15/14
P/E TM
--
Dividend
€0.09
Dividend Yield
4.03%
Current Stock Chart for FAES FARMA SA (FFEA)

Related News

No related news articles were found.

faes farma sa (FFEA) Related Businessweek News

No Related Businessweek News Found

faes farma sa (FFEA) Details

Faes Farma, S.A. is engaged in the research, development, manufacture, marketing, and sale of pharmaceutical products and raw materials in Spain, Portugal, and internationally. The company offers prescription, OTC, and skin-care treatment products. Its products include Bilastine, a non-sedating antihistamine for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria in adults and children; F-97013-GD, an antipsychotic product, which is in pre-clinical phases; F-98214-TA, an antidepressant that is in pre-clinical phases; and Serotonin reuptake inhibitors. The company also manufactures raw materials, such as diosmin, hidrosmin, magnesium pidolate, and arginine aspartate, as well as granulated diosmin, glutodine, trimethropim, and pyrrolidone carboxylate. Faes Farma, S.A. was founded in 1933 and is headquartered in Bilbao, Spain.

Founded in 1933

faes farma sa (FFEA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

faes farma sa (FFEA) Key Developments

Faes Farma, S.A. Announces Earnings Results for the Year Ended December 2014

Faes Farma, S.A. announced earnings results for the year ended December 2014. For the year, the company's total revenues were EUR 198.1 million compared with EUR 193.3 million a year ago. The increase in the company's sales has mainly relied on the revenues obtained from Bilastine's licences linked to the fulfillment of certain milestones, on the positive development of the international business (exports grew by 24%) and animal nutrition, as well as on sales of the products marketed over the last years (specially Bilaxten and the anti-diabetic and anti-inflammatory licences) and the catalogue of mature products. EBITDA was EUR 42.2 million compared with EUR 36.2 million a year ago, helped by the increase in sales and the cost containment. EBIT was EUR 33.3 million compared with EUR 25.8 million a year ago. Profit before tax was EUR 32.8 million compared with EUR 24.2 million a year ago. Net profit was EUR 25.3 million compared with EUR 22.6 million a year ago. As on December 2014, the company's net debt was EUR 21 million.

Faes Farma, S.A. Presents at BIO-Europe Spring 2015, Mar-09-2015

Faes Farma, S.A. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Faes Farma Announces Earnings Results for the Third Quarter of 2014

Faes Farma announced earnings results for the third quarter of 2014. The company's net profits grew 4.2% over the equivalent period in 2013, reaching EUR 22.17 million (USD 27.8 million). Pre-tax profits stood at EUR 35.3 million - 6% higher than in the third quarter of 2013. According to Faes Farma, it has been a positive year for the company, since with the third-quarter results they have achieved the same level of net profits as that for the full year 2013 (EUR 22.6 million).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FFEA:GR €2.31 EUR +0.009

FFEA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Recordati SpA €19.15 EUR -0.08
Shire PLC 5,635 GBp -15.00
Procter & Gamble Co/The $78.39 USD -0.94
View Industry Companies
 

Industry Analysis

FFEA

Industry Average

Valuation FFEA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.5x
Price/Cash Flow 18.7x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FAES FARMA SA, please visit www.faes.es. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.